ライフサイエンスコーパス: once-daily

1 6 hr and fludrocortisone as a 50 mug tablet once daily).

2 reased creatine phosphokinase (n = 1; 150 mg once daily).

3 pidogrel [75 mg] plus aspirin [75 to 100 mg] once daily).

4 ts received parsaclisib monotherapy (5-45 mg once daily).

5 first month, followed by 150 IU per kilogram once daily).

6 scalating doses of mavorixafor, up to 400 mg once daily.

7 0 mg, abacavir 600 mg, and lamivudine 300 mg once daily.

8 followed by SER-287 once weekly, or SER-287 once daily.

9 enzalutamide at a dose of 160 mg or placebo once daily.

10 brafenib twice daily plus 2 mg of trametinib once daily.

11 ve 5 mg or 15 mg of ertugliflozin or placebo once daily.

12 ; then switched to 50 mg film-coated tablets once daily.

13 atio to receive 30 mg of SAGE-217 or placebo once daily.

14 patients received 5 mg of folic acid orally once daily.

15 aily plus tiotropium 2.5 mug two inhalations once daily.

16 ecommended phase 2 dose of umbralisib 800 mg once daily.

17 on (control) or 20, 40, or 80 mg telmisartan once daily.

18 ed 6 to <12 years received sofosbuvir 200 mg once daily.

19 ssment Method and Sour Seven) were completed once daily.

20 ve ruxolitinib cream (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily) or veh

21 f three higher ruxolitinib cream doses (0.5% once daily, 1.5% once daily, 1.5% twice daily).

22 Patients in the 0.5% once daily, 1.5% once daily, or 1.5% twice daily groups

23 xolitinib cream doses (0.5% once daily, 1.5% once daily, 1.5% twice daily).

24 t 1.5% twice daily (15 [45%] of 33) and 1.5% once daily (15 [50%] of 30) than were treated with vehic

25 gepant 10 mg once daily, 182 atogepant 30 mg once daily, 177 atogepant 60 mg once daily, 79 atogepant

26 ts: 178 received placebo, 92 atogepant 10 mg once daily, 182 atogepant 30 mg once daily, 177 atogepan

27 on: 186 received placebo, 93 atogepant 10 mg once daily, 183 atogepant 30 mg once daily, 186 atogepan

28 gepant 10 mg once daily, 183 atogepant 30 mg once daily, 186 atogepant 60 mg once daily, 86 atogepant

29 a starting dose of 13.5 mg oral pemigatinib once daily (21-day cycle; 2 weeks on, 1 week off) until

30 egravir's pharmacokinetics in children given once daily 25 mg film-coated tablets (approved by the SR

31 ether oral azithromycin (250 mg administered once daily 3 times a week for 2 years) would reduce resp

32 ce daily (6.2% vs. 1.5%, p = 0.003), but not once daily (3.0% vs. 0.7%, p = 0.10) enoxaparin.

33 30 mg once daily -3.8 (0.2; p=0.039), 60 mg once daily -3.6 (0.2; p=0.039), 30 mg twice daily -4.2 (

34 10 mg once daily -4.0 (0.3; p=0.024), 30 mg once daily -3.8 (0.2; p=0.039), 60 mg once daily -3.6 (0

35 erate-to-severe psoriasis were randomized to once-daily 30 mg (n = 14) or 100 mg (n = 7) PF-06700841

36 ystem) to receive placebo or atogepant 10 mg once daily, 30 mg once daily, 60 mg once daily, 30 mg tw

37 nt 10 mg once daily, 30 mg once daily, 60 mg once daily, 30 mg twice daily, or 60 mg twice daily, in

38 ting dose schedule-after the initial dose of once-daily 350 mug Triac, the daily dose was increased p

39 igraine days versus placebo: atogepant 10 mg once daily -4.0 (0.3; p=0.024), 30 mg once daily -3.8 (0

40 2 or less, and were given umbralisib orally once daily (400 mg, 600 mg, or 800 mg) and ibrutinib ora

41 mg, 600 mg, or 800 mg) and ibrutinib orally once daily (420 mg for chronic lymphocytic leukaemia or

42 Patients received once-daily 560 mg ibrutinib, 375 mg/m(2) intravenous rit

43 nfarction 48) demonstrated noninferiority of once-daily 60 mg (30 mg dose-reduced) edoxaban compared

44 placebo or atogepant 10 mg once daily, 30 mg once daily, 60 mg once daily, 30 mg twice daily, or 60 m

45 gepant 30 mg once daily, 177 atogepant 60 mg once daily, 79 atogepant 30 mg twice daily, and 87 atoge

46 gepant 30 mg once daily, 186 atogepant 60 mg once daily, 86 atogepant 30 mg twice daily, and 91 atoge

47 dy participants (N = 33) received GSK2838232 once daily across a range of doses (20-200 mg) with cobi

48 irus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhance

49 Recovery was achieved by 30 d of once-daily administration of P7C3-A20, a compound that s

50 In CKD rats, once-daily administration of PF-06869206 for 8 weeks ind

51 a 2:1 ratio to receive niraparib or placebo once daily after a response to platinum-based chemothera

52 In the conditioning phase, mice were given once-daily alternating injections of either GBP or salin

53 ted 3 days before HSCT, taken orally at 2 mg once daily and adjusted to maintain trough concentration

54 dacitinib twice daily; or 24 mg upadacitinib once daily and were evaluated by ileocolonoscopy at week

55 open-label spironolactone (starting at 25 mg once daily) and their baseline blood pressure medication

56 (two participants each in the placebo, 30 mg once-daily, and 60 mg once-daily groups, and one partici

57 AD although trough concentrations with 25 mg once daily appeared to be insufficient to completely inh

58 ercise session (so-called "twice-a-day" and "once-daily" approaches, respectively).

59 ) values for sTXB2 (ng/mL) compared with the once-daily arm: 4 (2.1-6.7; n = 79), 2.5 (1.4-5.65, n =

60 Umbralisib was given orally once daily at 800 or 1200 mg (initial formulation) or 40

61 Both treatments were given once daily at any time of day and it was recommended tha

62 once daily) to E/C/F/TAF (150/150/200/10 mg once daily) at week 12.

63 once daily) to E/C/F/TAF (150/150/200/10 mg once daily) at week 12.

64 Patients received once-daily bezafibrate (400 mg) or placebo for 21 days.

65 ninfected recipients, followed by 8 weeks of once-daily coformulated glecaprevir and pibrentasvir, ta

66 oxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduc

67 Patients received oral niraparib 300 mg once daily continuously, beginning on day 1 and every cy

68 ib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinu

69 g of darunavir boosted with 100 mg ritonavir once daily could show equivalent efficacy to continuatio

70 s/mL for at least 48 weeks, monotherapy with once-daily dolutegravir was noninferior to cART.

71 andard fluid restriction of <1000 ml/24 h, a once-daily dose of oral empagliflozin or placebo for 4 d

72 bserved for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit.

73 xposures in adults who had received a 600 mg once-daily dose.

74 At once-daily doses of 3 and 10 mg/kg, GLPG1205 reduced dis

75 nducted with 43 subjects assigned to receive once daily dosing of either placebo (n = 21) or JNJ-4216

76 irmed therapeutic rivaroxaban exposures with once-daily dosing in children with bodyweights of at lea

77 It is unclear whether the two once-daily dosing non-vitamin K antagonist oral anticoag

78 In this randomized, double-masked trial, once-daily dosing of netarsudil 0.02% was effective, con

79 biological half-life of 10.5 h, suggesting a once-daily dosing regimen.

80 elimination half-life (16-17 hours) support once-daily dosing.

81 herosclerotic cardiovascular (CV) disease to once-daily ertugliflozin 5 mg, 15 mg, or placebo.

82 more were randomly assigned to groups given once-daily etrasimod 1 mg (n = 52), etrasimod 2 mg (n =

83 PARbeta/delta) genes, in comparison with the once-daily exercise.

84 s) with HIV-1 RNA <50 copies/mL to switch to once-daily fixed-dose DTG/3TC or remain on a tenofovir a

85 URY-1) investigated efficacy and safety of a once-daily, fixed-dose combination (FDC) of netarsudil a

86 HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300

87 , nasogastric, or intravenous administration once daily for 10 days) plus standard of care or to stan

88 noculation, cynomolgus macaques were treated once daily for 12 days with vehicle, 5 mg/kg remdesivir,

89 utaneous NGM282 (1 mg, n = 24; 3 mg, n = 19) once daily for 12 weeks were evaluated blinded to time p

90 tinib 100 mg, abrocitinib 200 mg, or placebo once daily for 12 weeks.

91 vir (400 mg) and velpatasvir (100 mg) tablet once daily for 12 weeks.

92 last 0.15% cream, or vehicle (placebo) cream once daily for 12 weeks.

93 g dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision);

94 tegravir group), each with matching placebo, once daily for 144 weeks.

95 tegravir group), each with matching placebo, once daily for 144 weeks.

96 , 30 mg (n = 56), or placebo (n = 28) orally once daily for 24 weeks.

97 0 mg of brensocatib, or 25 mg of brensocatib once daily for 24 weeks.

98 mg versus matching placebo was taken orally once daily for 26 weeks followed by nilotinib 300 mg ver

99 00, 200, 300, or 400 mg) or matching placebo once daily for 28 days.

100 randomized (2:1) to GB001 (30 mg) or placebo once daily for 28 days.

101 temisinin-piperaquine (20 mg/160 mg tablets) once daily for 3 consecutive days every 4 weeks or 12 we

102 and efficacy of oral pyronaridine-artesunate once daily for 3 consecutive days in adults and children

103 inary tract infections with cefixime (400 mg once daily for 3 days) or oral nitrofurantoin (100 mg tw

104 lower-dose (450 mg twice daily on day 1 and once daily for 4 days) therapy, was stopped owing to con

105 hours after induction of pneumonia, and then once daily for 4 days.

106 twice daily) for 2 months followed by 200 mg once daily for 4 months or placebo (same regimen).

107 ly for a month, twice daily for a month, and once daily for 4 months.

108 ) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle).

109 daily or 50 mg sunitinib monotherapy orally once daily for 4 weeks per 6-week cycle.

110 re and after PPI therapy (pantoprazole 40 mg once daily for 4 weeks).

111 ebo (n = 49), both provided in capsule form, once daily for 52 weeks.

112 ive HCQ (800 mg on day 1, followed by 400 mg once daily for 6 days) or no antiviral treatment (not-pl

113 -1a (144 patients) or placebo (152 patients) once daily for 6 days.

114 were randomized to oral JNJ-8678 or placebo once daily for 7 days.

115 daily plus azithromycin at a dose of 500 mg once daily for 7 days.

116 to nicotine (0.2 or 0.4 mg/kg, subcutaneous) once daily for 7 days.

117 ycin-loaded leukosomes (Leuko-Rapa; 5 mg/kg) once daily for 7 days.

118 ibrentasvir (300 mg/120 mg) was given orally once daily for 8 weeks (for patients without cirrhosis)

119 lus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatm

120 /kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but st

121 zed to use netarsudil (off-label) or placebo once daily for 9 months after Descemet membrane endothel

122 mg once daily; intermittent dosing at 20 mg (once daily for 9 weeks, then once weekly) was explored.

123 r Mental Disorders, Fifth Edition, criteria) once daily for a maximum of 5 days.

124 400 mug oral vitamin K2 or matching placebo once daily for a year.

125 tly recommended aspirin regimen of 75 to 100 once daily for cardiovascular prophylaxis appears to be

126 inistered adrenocorticotropic hormone (ACTH) once daily for four days to free-ranging juvenile northe

127 ther donepezil or isovolumetric water (i.g.) once daily for four days.

128 red intraperitoneally at two different doses once daily for ten days to healthy minipigs.

129 a dose of 200 IU per kilogram of body weight once daily for the first month, followed by 150 IU per k

130 f RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and/or invasive c

131 of eflornithine, 150 mg of sulindac, or both once daily for up to 48 months.

132 (10 mg) and saxagliptin (2.5 mg), or placebo once-daily for 24 weeks.

133 intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care a

134 t tumor recurrence (IBTR) between 30 Gy in 5 once-daily fractions (APBI arm) and 50 Gy in 25 fraction

135 with external APBI using IMRT technique in 5 once-daily fractions is low and not different from that

136 subdural haematoma; one patient in the 1.5% once daily group had a seizure; one patient in the 0.5%

137 group had a seizure; one patient in the 0.5% once daily group had coronary artery occlusion; and one

138 rtery occlusion; and one patient in the 0.5% once daily group had oesophageal achalasia), all of whic

139 l group in addition to patients in the 0.15% once daily group who did not show a 25% or higher improv

140 aily group; and six [19%] of 31 in the 0.15% once daily group)with three [9%] of 32 patients showing

141 0.15% once daily group, 31 (20%) to the 0.5% once daily group, 30 (19%) to the 1.5% once daily group,

142 to the control group, 31 (20%) to the 0.15% once daily group, 31 (20%) to the 0.5% once daily group,

143 0.5% once daily group, 30 (19%) to the 1.5% once daily group, and 33 (21%) to the 1.5% twice daily g

144 e daily group; three [10%] of 31 in the 0.5% once daily group; and six [19%] of 31 in the 0.15% once

145 e daily group; three [10%] of 30 in the 1.5% once daily group; three [10%] of 31 in the 0.5% once dai

146 ily groups, and one participant in the 10 mg once-daily group).

147 b 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-da

148 group, 1.69+/-4.69 in the evobrutinib 75-mg once-daily group, 1.15+/-3.70 in the evobrutinib 75-mg t

149 in the placebo, 30 mg once-daily, and 60 mg once-daily groups, and one participant in the 10 mg once

150 sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions dur

151 pazopanib (if patients <18 years 350 mg/m(2) once daily; if patients >=18 years 600 mg once daily) or

152 Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or

153 mg, children [<16 years] 40 mg/m(2)) orally once daily in 28-day cycles until disease progression, u

154 e of four) to either tivozanib 1.5 mg orally once daily in 4-week cycles or sorafenib 400 mg orally t

155 inistered orally at a dose of 560 and 420 mg once daily in 46% and 54% of patients, respectively; sym

156 OATD-01 given orally once daily in a range of doses between 30 and 100 mg/kg

157 g dose of 30 mg, with increasing dose levels once daily in continuous 28-day cycles until the maximum

158 to oral ivosidenib 500 mg or matched placebo once daily in continuous 28-day cycles, by means of an i

159 acokinetics (PK) of dolutegravir (DTG) 50 mg once daily in PLWH aged 60 and older.

160 Oral avapritinib was administered once daily in the dose-escalation part (starting dose of

161 tered orally (100 mg twice daily to 1,200 mg once daily) in continuous 28-day cycles.

162 ol, 1 mg, and norethindrone acetate, 0.5 mg, once daily) in women with fibroid-associated bleeding.

163 o receive either placebo or patiromer (8.4 g once daily), in addition to open-label spironolactone (s

164 eatment with placebo or empagliflozin (10 mg once daily), in addition to recommended treatments for h

165 raglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy.

166 (26%) in fasted adults on dolutegravir 50 mg once-daily; in children weighing 25 kg to less than 30 k

167 ixty-two patients were randomized to receive once-daily IND/GLY (110/50 mug) for 14 days, followed by

168 School-supervised use of a once-daily inhaled corticosteroid regimen (supervised th

169 Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development

170 once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not

171 acy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2

172 Expansion doses were 20 and 30 mg once daily; intermittent dosing at 20 mg (once daily for

173 Once-daily, intra-tracheal injections of HO-exposed mice

174 a series of patients treated with netarsudil once daily is reported.

175 Patients on chronic once-daily low-dose aspirin (n = 245) were randomized (1

176 Once-daily low-dose aspirin is the recommended antithrom

177 study demonstrates that mavorixafor, 400 mg once daily, mobilizes neutrophil and lymphocytes in adul

178 = 108); or 40 mg of subcutaneous enoxaparin once daily (n = 105) or 2.5 mg of oral apixaban twice da

179 tients with GIST receiving ripretinib 150 mg once daily (n = 142) were alopecia (n = 88 [62.0%]), fat

180 daily (n = 3023) or 1 to 4 mg of glimepiride once daily (n = 3010) in addition to usual care.

181 re randomized to receive 5 mg of linagliptin once daily (n = 3023) or 1 to 4 mg of glimepiride once d

182 ptin, 5 mg once daily (n = 3494), or placebo once daily (n = 3485) added to usual care.

183 were randomized to receive linagliptin, 5 mg once daily (n = 3494), or placebo once daily (n = 3485)

184 an FAAH inhibitor (PF-04457845, 4 mg orally, once daily; n = 16) or placebo (n = 29) for 10 days.

185 URTI symptoms were randomized to 14 days of once-daily nebulized AZD9412 or placebo.

186 Randomization to once-daily netarsudil 0.02%/latanoprost 0.005% FDC (n =

187 Once-daily netarsudil/latanoprost FDC demonstrated IOP r

188 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0.02%,

189 of effectiveness and safety between the two once-daily NOACs in a large-scale Asian AF population.

190 l patients received 225 mg ensartinib orally once daily on a continuous dosing schedule.

191 two through nine), oral melphalan (9 mg/m(2) once daily on days 1 through 4 of each cycle), and oral

192 each cycle), and oral prednisone (60 mg/m(2) once daily on days 1 through 4 of each cycle).

193 ch cycle intravenously and prednisone 100 mg once daily on days 1 to 5 of each cycle orally, followed

194 e (1,000 mg/m(2) days 1 and 8) with AZD1775 (once daily on days 1, 2, 8, and 9).

195 d capsules in 3.0 mg and 4.0 mg doses orally once daily on days 1-5 followed by 2 days off (5-7-day s

196 n day 1 intravenously, and prednisone 100 mg once daily on days 1-5 of each 21-day cycle orally (CHP)

197 o empagliflozin of 10 mg or matching placebo once daily on guideline-driven HF therapy for 12 weeks.

198 Consequently simulated, weight-banded once-daily optimal doses for children were lower than th

199 avir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily), plus two

200 nary disease to receive 0.5 mg of colchicine once daily or matching placebo.

201 e technology to take oral upadacitinib 15 mg once daily or oral placebo for the 14-week period 1; onl

202 c who were randomized to empagliflozin 25 mg once daily or placebo for 6 weeks with a 2-week washout

203 ce to either subcutaneous liraglutide 1.8 mg once daily or placebo, both given together with a reduce

204 randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and >=65 y

205 difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor

206 00, 600, or 1000 mg) or matching placebo, or once-daily or twice-daily doses of ABI-H0731 800 mg or m

207 aroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogr

208 weeks after tuberculosis therapy, then 50 mg once daily) or efavirenz (EFV; 600 mg daily) with 2 nucl

209 taneous enoxaparin 4,000 international units once daily) or high regimen thromboprophylaxis (i.e. sub

210 :1 ratio to receive oral upadacitinib (15 mg once daily) or intravenous abatacept, each in combinatio

211 to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chem

212 1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) fo

213 eceive oral apalutamide (four 60 mg tablets, once daily) or matching placebo.

214 0 mg twice daily) plus oral trametinib (2 mg once daily) or matching placebos for 12 months.

215 lazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g every 8 hours), with optio

216 y to either receive oral rosuvastatin (10 mg once daily) or no intervention (control) throughout clin

217 2) once daily; if patients >=18 years 600 mg once daily) or not (control group), with pazopanib not g

218 feron alfa-2a weekly plus either TDF (300 mg once daily) or placebo for 96 weeks.

219 5% to receive vericiguat (target dose, 10 mg once daily) or placebo, in addition to guideline-based m

220 o receive either low-dose colchicine (0.5 mg once daily) or placebo.

221 n system to receive oral dolutegravir (50 mg once daily) or ritonavir-boosted lopinavir (800 mg lopin

222 of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.

223 , 1.5% once daily, 0.5% once daily, or 0.15% once daily) or vehicle (control group) twice daily on le

224 eam (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily) or vehicle (control gro

225 Patients in the 0.5% once daily, 1.5% once daily, or 1.5% twice daily groups remained at their

226 sizes of 4 within each country, to adjuvant once daily oral cenobamate at dose groups of 100 mg, 200

227 fenamide 25 mg and emtricitabine 200 mg, and once-daily oral dolutegravir 50 mg; once-daily oral fixe

228 umarate 300 mg and emtricitabine 200 mg, and once-daily oral dolutegravir 50 mg; or once-daily oral f

229 (MS) (aged 10-<18 years) were randomised to once-daily oral fingolimod (n=107) or once-weekly intram

230 , and once-daily oral dolutegravir 50 mg; or once-daily oral fixed-dose combination of tenofovir diso

231 Participants were randomly assigned to once-daily oral fixed-dose combination tenofovir alafena

232 mg, and once-daily oral dolutegravir 50 mg; once-daily oral fixed-dose combination tenofovir disopro

233 Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has

234 Once-daily oral omadacycline was non-inferior to twice-d

235 re to at least 12 months treatment of either once-daily oral ozanimod 1.0 mg or 0.5 mg or weekly intr

236 maintenance dose coadministered with 600 mg once-daily oral rifampicin.

237 owering medication and country of origin, to once-daily oral semaglutide (dose escalated to 14 mg), o

238 as conducted to evaluate ZPL-3893787 (30 mg) once-daily oral therapy in adults with moderate-to-sever

239 lass II or III are randomized 1:1 to receive once-daily, oral mavacamten, or matching placebo for 30

240 mg) once daily orally plus prednisone (5 mg) once daily orally and ADT (abiraterone acetate plus pred

241 Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenousl

242 :1) to receive abiraterone acetate (1000 mg) once daily orally plus prednisone (5 mg) once daily oral

243 mg once daily (ripretenib group) or placebo once daily (placebo group).

244 g factor) versus abiraterone (1000 mg orally once daily plus 5 mg prednisone twice daily) or enzaluta

245 to receive oral abiraterone acetate 1000 mg once daily plus oral prednisone or prednisolone 5 mg twi

246 lone (minimal care group) or together with a once-daily polypill tablet (polypill group).

247 eurotoxicity remains frequent in patients on once-daily prolonged-release tacrolimus.

248 dolutegravir 50 mg film-coated tablets given once daily provide appropriate pharmacokinetic profiles

249 5) were randomized to receive VT-1161 300 mg once daily (q.d.) for 3 days, 600 mg q.d. for 3 days, or

250 was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of t

251 utinib at 100 mg twice daily (BID) or 200 mg once daily (QD) in 48 patients with relapsed/refractory

252 atients were randomized to PF-06700841 30 mg once daily (QD), 60 mg QD, or placebo (4-week induction)

253 ted, with the estimated half-life supporting once-daily (QD) dosing.

254 eatment to RUX (1.5% twice daily [BID], 1.5% once daily [QD], 0.5% QD, 0.15% QD), vehicle, or triamci

255 Gemcitabine and once daily radiation (GD) is a well-supported alternativ

256 Either gemcitabine and once daily radiation or a cisplatin-based regimen could

257 8-0.63, P-score 0.99), and prucalopride 2 mg once daily ranked first at 12 weeks (0.82, 0.78-0.86, P-

258 0 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events a

259 irin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adverse cardiovascu

260 :1) to receive either oral ripretinib 150 mg once daily (ripretenib group) or placebo once daily (pla

261 articipants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasv

262 articipants received sofosbuvir/velpatasvir (once-daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasv

263 f an efficacy outcome from the IMPACT trial, once-daily single-inhaler FF/UMEC/VI triple therapy redu

264 rallel-group, 52-week global study comparing once-daily single-inhaler triple therapy (fluticasone fu

265 The IMPACT trial showed that once-daily single-inhaler triple therapy significantly r

266 In children with achondroplasia, once-daily subcutaneous administration of vosoritide was

267 acebo-controlled, multicentre trial compared once-daily subcutaneous administration of vosoritide wit

268 equential cohorts to receive vosoritide at a once-daily subcutaneous dose of 2.5 mug per kilogram of

269 oral semaglutide (dose escalated to 14 mg), once-daily subcutaneous liraglutide (dose escalated to 1

270 mong those who received 0.5 mg of colchicine once daily than among those who received placebo.

271 e therapy, which usually is omeprazole 20 mg once daily, the aim is to use the lowest effective dose.

272 s were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesart

273 gravir (50 mg) plus lamivudine (300 mg) or a once-daily three-drug regimen of dolutegravir (50 mg) pl

274 rwent open-label nabilone titration (0.25 mg once daily to 1 mg twice daily, phase I).

275 or placebo) and fatigue (1% [1/93] for 10 mg once daily to 10% [9/91] for 60 mg twice daily vs 3% [6/

276 roups were nausea (range 5% [5/93] for 10 mg once daily to 12% [22/186] for 60 mg once daily vs 5% [9

277 frequency ranged from 18% (17/93) for 10 mg once daily to 26% (24/91) for 60 mg twice daily, versus

278 Roflumilast cream administered once daily to affected areas of psoriasis was superior t

279 nt opioid agonist therapy (OAT) and compared once-daily to twice-daily DAA therapy.

280 nt opioid agonist therapy (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct

281 switched from E/C/F/TDF (150/150/200/300 mg once daily) to E/C/F/TAF (150/150/200/10 mg once daily)

282 roxil fumarate (E/C/F/TDF 150/150/200/300 mg once daily) to E/C/F/TAF (150/150/200/10 mg once daily)

283 irst-in-human study in postmenopausal women, once daily treatment with BAY 1214784 effectively lowere

284 randomly assigned in a 1:1 ratio to receive once-daily treatment with SEP-363856 (50 mg or 75 mg) or

285 mly assigned participants (1:1) to receive a once-daily two-drug regimen of dolutegravir (50 mg) plus

286 150 mg twice daily and oral trametinib 2 mg once daily until disease progression or intolerance of t

287 nse system and stratified geographically, to once-daily upadacitinib oral monotherapy 7.5, 15, or 30

288 xaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the

289 ally twice daily plus trametinib 2 mg orally once daily versus two matched placebos.

290 r 10 mg once daily to 12% [22/186] for 60 mg once daily vs 5% [9/186] for placebo) and fatigue (1% [1

291 with higher adherence among those receiving once-daily vs twice-daily therapy (94% vs 87%, P = .005)

292 14% of patients receiving 24 mg upadacitinib once daily, vs 11% of patients receiving placebo.

293 Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescen

294 dose evaluated, 200 mg twice a day); 150 mg once daily was established as the RP2D.

295 OCA (25 mg orally once daily) was better than placebo in improving MRI-PDF

296 l and sodium picosulfate, at a dose of 10 mg once daily, were ranked first at 4 weeks (RR 0.55, 95% C

297 n film-coated tablet doses of 25 mg or 35 mg once daily, which were approved by the SRAs for the chil

298 ased PrEP is expensive and needs to be taken once-daily, which often leads to inadequate adherence an

299 1 to either oral vancomycin (dosed at 125 mg once daily while receiving systemic antibiotics and cont

300 omized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target internat